207 related articles for article (PubMed ID: 19916023)
1. Expression of metalloproteases and their inhibitors in different histological types of breast cancer.
Del Casar JM; González-Reyes S; González LO; González JM; Junquera S; Bongera M; García MF; Andicoechea A; Serra C; Vizoso FJ
J Cancer Res Clin Oncol; 2010 Jun; 136(6):811-9. PubMed ID: 19916023
[TBL] [Abstract][Full Text] [Related]
2. Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events.
González LO; González-Reyes S; Junquera S; Marín L; González L; Del Casar JM; González JM; Vizoso F
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1313-21. PubMed ID: 20127359
[TBL] [Abstract][Full Text] [Related]
3. Low microvascular density at the tumor center is related to the expression of metalloproteases and their inhibitors and with the occurrence of distant metastasis in breast carcinomas.
Fernández-Guinea O; Álvarez-Cofiño A; Eiró N; González LO; del Casar JM; Fernandez-Garcia B; Lamelas ML; Andicoechea A; Vizoso FJ
Int J Clin Oncol; 2013 Aug; 18(4):629-40. PubMed ID: 22688161
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.
Fernandez-Garcia B; Eiró N; Marín L; González-Reyes S; González LO; Lamelas ML; Vizoso FJ
Histopathology; 2014 Mar; 64(4):512-22. PubMed ID: 24117661
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors.
Gonzalez LO; Corte MD; Vazquez J; Junquera S; Sanchez R; Alvarez AC; Rodriguez JC; Lamelas ML; Vizoso FJ
BMC Cancer; 2008 May; 8():149. PubMed ID: 18507821
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
7. Expression and Clinical Significance of Metalloproteases and Their Inhibitors by Endothelial Cells From Invasive Breast Carcinomas.
Cid S; Eiro N; González LO; Beridze N; Vazquez J; Vizoso FJ
Clin Breast Cancer; 2016 Aug; 16(4):e83-91. PubMed ID: 27266802
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
9. Invasive breast cancer: a significant correlation between histological types and molecular subgroups.
Caldarella A; Buzzoni C; Crocetti E; Bianchi S; Vezzosi V; Apicella P; Biancalani M; Giannini A; Urso C; Zolfanelli F; Paci E
J Cancer Res Clin Oncol; 2013 Apr; 139(4):617-23. PubMed ID: 23269487
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.
Kim GE; Lee JS; Choi YD; Lee KH; Lee JH; Nam JH; Choi C; Kim SS; Park MH; Yoon JH; Kweon SS
BMC Cancer; 2014 Dec; 14():959. PubMed ID: 25510449
[TBL] [Abstract][Full Text] [Related]
11. Patterns of distribution of cytokeratins 20 and 7 in special types of invasive breast carcinoma: a study of 123 cases.
Tot T
Ann Diagn Pathol; 1999 Dec; 3(6):350-6. PubMed ID: 10594286
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumour stromal mononuclear inflammatory cells and those at the invasive front of breast carcinomas.
González LO; González-Reyes S; Marín L; González L; González JM; Lamelas ML; Merino AM; Rodríguez E; Pidal I; del Casar JM; Andicoechea A; Vizoso F
Histopathology; 2010 Dec; 57(6):862-76. PubMed ID: 21166700
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas.
Del Casar JM; González LO; Alvarez E; Junquera S; Marín L; González L; Bongera M; Vázquez J; Vizoso FJ
Breast Cancer Res Treat; 2009 Jul; 116(1):39-52. PubMed ID: 19241156
[TBL] [Abstract][Full Text] [Related]
14. Mucin expression in mucinous carcinoma and other invasive carcinomas of the breast.
Chu JS; Chang KJ
Cancer Lett; 1999 Jul; 142(1):121-7. PubMed ID: 10424790
[TBL] [Abstract][Full Text] [Related]
15. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study.
Brummer O; Athar S; Riethdorf L; Löning T; Herbst H
Virchows Arch; 1999 Dec; 435(6):566-73. PubMed ID: 10628798
[TBL] [Abstract][Full Text] [Related]
16. Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast.
Gonzalez LO; Corte MD; Vazquez J; Junquera S; Sanchez R; Viña A; Rodriguez JC; Lamelas ML; Vizoso F
Histopathology; 2008 Oct; 53(4):403-15. PubMed ID: 18983606
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of different histologic types of breast cancer.
Li CI; Uribe DJ; Daling JR
Br J Cancer; 2005 Oct; 93(9):1046-52. PubMed ID: 16175185
[TBL] [Abstract][Full Text] [Related]
18. Study of matrix metalloproteinases and their inhibitors in breast cancer.
Vizoso FJ; González LO; Corte MD; Rodríguez JC; Vázquez J; Lamelas ML; Junquera S; Merino AM; García-Muñiz JL
Br J Cancer; 2007 Mar; 96(6):903-11. PubMed ID: 17342087
[TBL] [Abstract][Full Text] [Related]
19. Role of PRL-3, Snail, Cytokeratin and Vimentin expression in epithelial mesenchymal transition in breast carcinoma.
Patel NA; Patel PS; Vora HH
Breast Dis; 2015; 35(2):113-27. PubMed ID: 25547164
[TBL] [Abstract][Full Text] [Related]
20. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival.
Nakopoulou L; Tsirmpa I; Alexandrou P; Louvrou A; Ampela C; Markaki S; Davaris PS
Breast Cancer Res Treat; 2003 Jan; 77(2):145-55. PubMed ID: 12602913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
